The Irvine, Calif.-based company is hoping to raise the funds to cover “general corporate purposes, which may include working capital, continued investment in geographic expansion, research and development and clinical studies,” according to a press release. The notes are expected to become due by December 2018.
Endologix had strong sales in its 3rd quarter, but couldn’t keep up with Wall Street guidance. The aortic disorders device manufacturer posted losses of $9.5 million, or 14¢ per share, on sales of $33.3 million for the 3 months ended Sept. 30. That’s a profit slide of 57.9% on sales growth of 24.6% compared with the same period last year.